Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration for Total Abdominal Hysterectomy

TC Erciyes University

Status and phase: Completed; Phase 4

Conditions: Pain

Treatments: Drug: Dexmedetomidine; Drug: Levobupivacaine

Study type: Interventional

Funder types: Other

Identifiers

NCT01929252

2011/07

Details and patient eligibility

About

The aim of this study was to investigate the analgesic efficacy of dexmedetomidine administration in wound infiltration for total abdominal hysterectomy.

Full description

Abdominal hysterectomy is associated with moderate to severe postoperative pain, effective analgesia after hysterectomy essential and several techniques are used such as administration of opioids, nonsteroidal anti-inflammatory drugs and wound infiltration of local anaesthetics. Different local anaesthetics can be used for the wound infiltration techniques.Ifiltration of the surgical wound with bupivacaine following outpatient provides pain relief in the postoperative period , allows the early discharge from the outpatient surgical units.There has been increased interest in administration of analgesic prior to surgical injury. Dexmedetomidine is a highly selective alpha-2 adrenergic agonist with sedative , anxiolytic, analgesic, sympatholytic and antihypertensive effects.Dexmedetomidine has been used intravenously before initiation of anaesthesia and it has shown to provide some analgesic effect after surgery but there were some adverse hemodynamic effects. Surgical wound administration of dexmedetomidine may be useful to avoid the adverse haemodynamic effects of intravenous administration while still providing the postoperative analgesia.

Enrollment: 50 patients

Sex: Female

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18-65 yo female
• scheduled for elective hysterectomy
• no known allergies to drugs
• ASA 1=2 patients

Exclusion criteria

• history of diabetes
• history of chronic pain treatment
• pregnancy

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

50 participants in 2 patient groups

Dexmedetomidine

Active Comparator group

Description:

%0.25 40 ml levobupivacaine and 2 mcg/kg dexmedetomidine administered via wound infiltration just before the incision.

Treatment:

Drug: Levobupivacaine

Drug: Dexmedetomidine

Levobupivacaine

Active Comparator group

Description:

%0.25 40 ml levobupivacaine administered via wound infiltration prior to incision.

Treatment:

Drug: Levobupivacaine